KPTI · Karyopharm Therapeutics Inc.

Summary

Karyopharm Therapeutics Inc. entered a Securities Purchase Agreement with RA Capital Management to issue shares, pre-funded warrants, and common stock warrants in a private placement expected to yield $30 million gross proceeds, with potential additional $44 million upon warrant exercise. The company announced topline results from the Phase 3 SENTRY trial meeting the SVR35 co-primary endpoint with 50% of patients achieving spleen volume reduction versus 28% on ruxolitinib alone.

Key takeaways

• Event Type: Private Placement Financing and Phase 3 SENTRY Trial Topline Results (Items: 1.01, 3.02, 7.01)